The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

ASCO 2022 | ADCs in lymphoma

Name: ADCs in lymphoma
Uploaded: 2022-06-04T00:00:00Z
Duration: 1 min 17 s
Description: Stephen M. Ansell, MD, PhD, Mayo Clinic, Rochester, MN, gives his highlights from the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting, emphasizing the promise of antibody-drug conjugates (ADCs) in lymphoma which represent a new frontier in oncology. This interview took place at the ASCO 2022 Annual Meeting in Chicago, IL.

Stephen Ansell • 4 Jun 2022

ASCO 2022

Hodgkin Lymphoma Lymphoma Antibodies CAR-T

Stephen M. Ansell, MD, PhD, Mayo Clinic, Rochester, MN, gives his highlights from the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting, emphasizing the promise of antibody-drug conjugates (ADCs) in lymphoma which represent a new frontier in oncology. This interview took place at the ASCO 2022 Annual Meeting in Chicago, IL.